5-Bromo-2-chloropyrimidine

We are 5-Bromo-2-chloropyrimidine CAS:32779-36-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 5-Bromo-2-chloropyrimidine
CAS.NO: 32779-36-5
Synonyms:
PYRIMIDINE,5-BROMO-2-CHLORO
5-BROMO-2-CHLOROPYRIMIDNE
2-CHLORO-5-BROMOPYRIMIDINE
2-chloro-5-bromopyrimidine(5-bromo-2-chloropyrimidine)
5-Bromo-2-chloro-1,3-diazine
2,5-bromochloro pyrimidine
2-chloro-5-bromopyridine

Molecular Formula:C4H2BrClN2
Molecular Weight:193.42900

Physical and Chemical Properties:
Density: 1.86 g / cm3
Boiling point: 95 ° C 15mm
Melting point: 76-81 ° C (lit.)
Flash point: 95 ° C / 15mm
Refractive index: 1.588

Specification:
Appearance: White or off-white powder
Purity:≥98%
Water:≤0.3%
Residue on ignition:≤0.5%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Macitentan CAS:441798-33-0

Related News: GlaxoSmithKline’s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.(S,S)-2,8-Diazabicyclo[4,3,0]Nonane GlaxoSmithKline’s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.4-Bromo-4',4''-dimethyltriphenylamine CAS:58047-42-0 Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).106877-33-2 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.